AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03089528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laringoscope
Description: the trachea will be intubated with a laringoscope
Study NCT02226328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Study NCT02226328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and Fentanyl sedation
Study NCT02907528 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone
Description: Furcation defect regenerated with bone graft material
Study NCT02907528 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: Furcation defect regenerated with EMD
Study NCT02907528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD
Description: Furcation defect regenerated with EMD
Study NCT05504538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
Description: arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
Study NCT05504538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tight rope
Description: Adjustable button device from Arthrex Naples USA
Study NCT02388815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed.
Study NCT02280746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten challenge
Description: Intervention will be continued for at least 6 months
Study NCT01296945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk
Description: Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
Study NCT01296945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper
Description: Participants will receive a paper handout with nutrition educational information.
Study NCT01296945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk PLUS paper
Description: Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
Study NCT02512354 — intervention group
Intervention type: OTHER
Intervention: Sample of a fragment of fetal tissue
Study NCT02512354 — intervention group
Intervention type: OTHER
Intervention: Parent's blood samples
Study NCT01832805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation.
Description: In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
Study NCT04592354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxaloacetate Medical Food/Dietary Supplement
Description: 500 mg Anhydrous Enol-Oxaloacetate BID
Study NCT04592354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxaloacetate Medical Food/Dietary Supplement
Description: 500 mg Anhydrous Enol-Oxaloacetate BID
Study NCT00440596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: 8 weeks group MBSR
Study NCT01296945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk PLUS web
Description: Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
Study NCT02940418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adipose mesenchymal cells with bone marrow mononuclear cells
Description: Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
Study NCT02701127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03299426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Description: Single 0.5-ml intramuscular injection
Study NCT03299426 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal A Conjugate Vaccine (MCV-A)
Description: Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
Study NCT01280032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
Study NCT04236661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chilipad
Description: Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
Study NCT00675428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Study NCT01248052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: administered orally
Study NCT01248052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally
Study NCT02610543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
Study NCT02610543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
Study NCT01902810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization
Study NCT00440596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: 8 weeks PMR in group format
Study NCT06104696 — intervention group
Intervention type: PROCEDURE
Intervention: Functional geriatric assessment
Description: Examination of physical and mental status using standardized tests.
Study NCT01902810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth given daily throughout hospitalization
Study NCT03008265 — intervention group
Intervention type: OTHER
Intervention: Postoperative fascial dehiscence
Study NCT03209141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diastolic function evaluation
Description: Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
Study NCT04115475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study NCT04115475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study NCT00771017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX prostate cancer vaccine
Description: Given intradermally
Study NCT00771017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally
Study NCT00771017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally
Study NCT00771017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: Given intramuscularly
Study NCT00771017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Given intramuscularly
Study NCT00771017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Given intramuscularly
Study NCT00771017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given intramuscularly
Study NCT04484974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan snack
Description: Under this condition, each participant will consume a mid morning snack of pecans followed by an ad libitum lunch.
Study NCT04484974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tortilla chip snack
Description: Under this condition, each participant will consume a mid morning snack consisting of an iso-caloric (equal to the pecan snack) snack of tortilla chips followed by an ad libitum lunch.
Study NCT02487472 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
Study NCT03885102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise intervention
Description: 50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling
Study NCT03885102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care with no exercise intervention or health literacy counselling
Study NCT00132002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT00132002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03141489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tubefeeding
Description: NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
Study NCT01787474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01787474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01787474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study NCT01787474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01787474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01787474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Description: Given IV
Study NCT03182179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: Ondansetron is taken orally BD
Study NCT03182179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken orally BD
Study NCT04210895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger powder footbath
Description: 40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
Study NCT04210895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm water only footbath
Description: 40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
Study NCT02093689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
Study NCT02093689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
Study NCT02093689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 2 Placebo
Description: Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
Study NCT05728632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol, capsule, 5 mg once daily, for 12 months
Study NCT05728632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsule, once daily, for 12 months
Study NCT01679132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO System and Medical Management
Description: Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators.
Study NCT02229240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
Study NCT02229240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching albiglutide placebo
Description: Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
Study NCT01579474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 high dose
Description: BI 201335 high dose with PegIFN/RBV
Study NCT01579474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 low dose
Description: BI 201335 low dose with PegIFN/RBV
Study NCT03182608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasound assessment
Description: An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
Study NCT03204591 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01567306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study NCT01567306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study NCT01567306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study NCT01567306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study NCT01567306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study NCT01567306 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study NCT04296357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
Study NCT03075059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life
Description: For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
Study NCT00462280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: Given PO
Study NCT00462280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00462280 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies
Study NCT00462280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT00462280 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00462280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04859582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered as a continuous IV infusion on Days 1-5 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered as a continuous IV infusion on Days 1-5 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally BID on Days 1 to 14 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally BID on Days 1 to 14 Q3W
Study NCT04859582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT01303081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Rewards
Description: If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
Study NCT01303081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Deposits
Description: Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.